Search the Newsreel

Able View Global Inc (ABLV) Earnings Forecast: Future EPS & Revenue Growth Estimates

Grupo Supervielle's Q2 Adjusted Earnings Decline

Grupo Supervielle (SUPV) reported a decline in its Q2 adjusted earnings, with figures reaching 146.70 Argentine pesos ($0.10). The full details of the report are available to subscribers of premium news services.

RXO, BrightView, SiteOne, ServiceNow, and Rocket Lab Shares Are Soaring, What You Need To Know

RXO, BrightView, SiteOne, ServiceNow, and Rocket Lab Shares Are Soaring, What You Need To Know What Happened? A number of stocks jumped in the afternoon session after the July jobs report showed an unexpected loss of 23,000 jobs, signaling a cooling labor market. Economists …

Pharma giants, including AbbVie, sue to block Illinois drug discount law

Major pharmaceutical companies, including AbbVie, Bristol Myers, and Novartis, have filed a lawsuit to block a new drug discount law in Illinois. The lawsuit challenges the state's 340B law, which aims to provide discounted prescription drugs. This legal action by the pharma giants indicates …

Grupo Supervielle (NYSE:SUPV) Issues Quarterly Earnings Results

Grupo Supervielle (NYSE:SUPV) reported quarterly earnings per share of $0.29, surpassing the consensus estimate of $0.13, despite posting negative net margins and return on equity. The company's stock fell to $8.48, trading below its moving averages, with a market capitalization of $742 million. Analysts …

Avient’s Earnings Call Highlights Margin Highs, Debt Wins

Avient Corporation (AVNT) reported strong Q2 earnings, exceeding expectations with adjusted EPS of $0.96 and a 20% year-over-year increase. The company highlighted record profitability, robust cash generation, and significant debt reduction, despite facing mixed demand in some sectors. Growth was particularly strong in Asia …

Grupo Supervielle: Q2 Earnings Snapshot

This article provides a snapshot of Grupo Supervielle's Q2 earnings. Due to the limited content provided, specific financial details are not available. The article indicates it's an earnings overview for the quarter.

Grupo Supervielle returns to profit in 2Q FY26 with AR$ 12.8 billion net income; net financial income rises 8.3% QoQ to AR$ 294.5 billion

Grupo Supervielle reported a return to profit in 2Q FY26 with a net income of AR$ 12.8 billion, a significant turnaround from a net loss in the previous quarter. The company's net financial income increased by 8.3% quarter-on-quarter to AR$ 294.5 billion, and its …

Supervielle Cuts Headcount 17% for AR$42B Annual Savings

Grupo Supervielle reported a return to profitability in 2Q26 with a net income of AR$12.8 billion, driven by an expanded net interest margin and strategic cost-cutting measures. The company reduced its headcount by 17% compared to year-end 2025, anticipating AR$42 billion in annualized personnel …

Grupo Supervielle Reports 2Q26 Results

⁠Return to profitability, with Adjusted ROAE of 12.4% excluding extraordinary severance charges from the rightsizing plan Group headcount reduced 17% vs. year-end 2025, with AR$42 billion in annualized personnel savings and full run-rate benefit from 3Q26 ⁠NPL ratio improved to 5.5%, 210 bps below …

Riverview Bancorp chief lending officer to retire in October

Riverview Bancorp (NASDAQ:RVSB) announced that Michael Sventek, Executive Vice President and Chief Lending Officer, will retire on October 30, 2026. Sventek has over 35 years of banking experience and helped diversify the company's loan portfolio. The company will begin searching for his successor next …

Riverview Bancorp (RVSB) announces retirement of Chief Lending Officer Michael Sventek

Riverview Bancorp (RVSB) announced that Executive Vice President and Chief Lending Officer Michael Sventek will retire on October 30, 2026, after a 35-year banking career. The company, which reported $1.47 billion in assets as of June 30, 2026, plans an extensive search for his …

Riverview executive to retire after more than 35 years in banking

Riverview Bancorp announced that Executive Vice President and Chief Lending Officer Michael Sventek will retire on October 30, 2026, after a distinguished banking career spanning over 35 years. President and CEO Nicole Sherman credited Sventek with significant contributions to the bank's growth strategies and …

Price to sales forward of Northview Residential REIT – TSX:NRR.UN

Navient (NASDAQ:NAVI) Shares Down 6.6% - Here's What Happened

Navient (NASDAQ:NAVI) shares dropped 6.6% to $8.48 on Monday, trading below average volume. Despite exceeding Q2 earnings and revenue expectations and offering a 7.5% annualized dividend yield, analyst sentiment remains cautious with a consensus "Reduce" rating and a target price of $9.14. Institutional investors …

AbbVie’s (ABBV) Botox Just Got A Step Closer To A Fifth Use

AbbVie's Botox Cosmetic has moved closer to FDA approval for a fifth aesthetic use: treating masseter muscle prominence. This potential approval is based on positive Phase 3 study results and aligns with AbbVie's strategy of expanding existing drug indications. While the company shows strong …

AbbVie, Novartis Sue Illinois Over Hospital Drug Pharmacy Law

AbbVie and Novartis AG have filed separate lawsuits against the state of Illinois, challenging a new law that regulates drugmakers' contractual agreements with pharmacies under a federal drug discount program. AbbVie claims the law violates its constitutional property rights by mandating the transfer of …

Is AbbVie Stock a Buy After Posting Strong Q2 Earnings?

BrightView Holdings Independent Director Acquires 37% More Stock

BrightView Holdings, Inc. (NYSE:BV) saw its Independent Director, William Cornog, purchase US$562k worth of shares at an average price of US$11.25, increasing his holding by 37%. This purchase comes despite significant insider selling over the past year by the CFO at a higher price. …

Why Viemed Healthcare's (NASDAQ:VMD) Earnings Are Better Than They Seem

Viemed Healthcare's recent earnings, despite seemingly weak stock performance, are better than they appear due to strong cash conversion. The company recorded a negative accrual ratio of -0.11, indicating its free cash flow of US$29m significantly exceeded its statutory profit of US$14.5m. Additionally, unusual …

AbbVie Stock After the Apogee Financing: What $10 Billion in Notes Signals.

AbbVie recently issued $10 billion in senior notes to finance its $10.9 billion acquisition of Apogee Therapeutics, with the deal expected to close on August 18. Despite narrowing full-year guidance due to acquisition-related dilution, AbbVie reported strong Q2 earnings driven by Skyrizi and Rinvoq …

AbbVie to Acquire Apogee Therapeutics for $10.9 Billion; Apogee Reports Positive Phase 2 Zumilokibart Data and Q2 2026 Results

AbbVie plans to acquire Apogee Therapeutics for $10.9 billion, or $135.11 per share, to bolster its immunology portfolio. This acquisition follows Apogee's positive Phase 2 results for zumilokibart in atopic dermatitis and a $1.3 billion financing deal with Blackstone Life Sciences. The deal is …

Apogee's Atopic Dermatitis Drug Shows 65.9% EASI-75

Apogee Therapeutics announced its Q2 2026 financial results and significant corporate updates, including AbbVie's agreement to acquire the company for approximately $10.9 billion. The acquisition, valued at $135.11 per share in cash, is expected to close in Q3 2026. Additionally, Apogee reported positive Phase …

AbbVie Inc. (ABBV) Stock Analysis: Evaluating Growth Potential With A 11.51% Upside

AbbVie Inc. (ABBV) is a biopharmaceutical company with a strong market presence, a current stock price of $246.04, and a potential upside of 11.51% according to analyst ratings. While the company boasts significant revenue growth, strong operational efficiency, and an attractive dividend yield, its …

AbbVie Inc. (NYSE:ABBV) Receives Average Recommendation of "Moderate Buy" from Brokerages

AbbVie Inc. (NYSE:ABBV) has received a "Moderate Buy" consensus rating from 24 brokerages, with an average 12-month price target of $275.70, exceeding its current share price. The company surpassed quarterly earnings expectations with adjusted EPS of $3.65 and revenue of $16.99 billion, marking a …

BrightView’s Q2 Earnings Call: Our Top 5 Analyst Questions

Is Avient (AVNT) Still Below Fair Value After Strong Earnings And Raised Guidance?

The 5 Most Interesting Analyst Questions From AbbVie’s Q2 Earnings Call

The 5 Most Interesting Analyst Questions From AbbVie's Q2 Earnings Call AbbVie's second quarter results reflected robust product performance but were met with cautious investor sentiment. Management credited double-digit sales growth to strong execution in core immunology therapies, especially SKYRIZI and RINVOQ, and notable …

BrightView Holdings (BV) As Earnings And Guidance Reset The Case For A Pricey Valuation

Navient Corp (NAVI) Earnings Forecast: Future EPS & Revenue Growth Estimates

Navient Corp (NAVI) has an earnings forecast score of 5.50, ranking 329th in the Banking Services industry. Analysts have set an average price target of $13.00, with current ratings suggesting a "Hold" trend. The company's expected revenue for the next quarter is $142.88 million, …

(BV) Movement as an Input in Quant Signal Sets

This article analyzes Brightview Holdings Inc. (NYSE: BV) using AI models to generate trading strategies. It highlights weak near and mid-term sentiment, a neutral long-term outlook, and an exceptional risk-reward setup targeting a 12.7% gain. The analysis provides specific entry, target, and stop-loss points …

Lazard Asset Management LLC Has $192,000 Stock Position in BrightView Holdings, Inc. $BV

Lazard Asset Management LLC significantly reduced its stake in BrightView Holdings, Inc. (NYSE:BV) by 89.9% in the first quarter, now holding 16,292 shares valued at $192,000. Despite institutional investors owning 92.41% of the company, BrightView missed analyst estimates for both EPS and revenue in …

3 US REITs For Dividend Income Before The July CPI Report

This article examines three US REITs—FrontView REIT (FVR), Modiv Industrial (MDV), and Lamar Advertising (LAMR)—that could be impacted by the upcoming July CPI report. It discusses their current market positions, dividend potential, and the risks associated with inflation, interest rates, and their financial structures. …

FrontView REIT, Inc. (NYSE:FVR) Receives Consensus Rating of "Moderate Buy" from Analysts

FrontView REIT, Inc. (NYSE:FVR) has received a "Moderate Buy" consensus rating from analysts, with an average 12-month price target of $21.83. The company recently raised its 2026 EPS guidance to $1.32–$1.34 and reported second-quarter EPS of $0.03, exceeding expectations, despite revenue falling short. Institutional …

AbbVie Inc (ABBV) Gewinnprognose: Zukünftige EPS & Umsatzwachstumsprognosen

Is BrightView Holdings (BV) Fairly Valued As Earnings And Guidance Reset Expectations?